Tune in for a deep dive into the evolving landscape of immuno-oncology (IO) in early-stage triple-negative breast cancer (TNBC). Our experts focus on identifying eligible patients for neoadjuvant and adjuvant IO regimens, understanding current and emerging treatment options, and effectively utilizing shared decision-making (SDM) techniques to tailor treatment plans. The activity also covers the importance of recognizing and managing immune-related adverse events (irAEs) in the perioperative setting. Learn to optimize the use of IO in early-stage TNBC and improve your patients’ outcomes and quality of life.